Lamivudine-Resistant Hepatitis B Virus and Ongoing Lamivudine Therapy: Stop the Merry-Go-Round,It'S Time to get off!

Torresi J. , & Locarnini S. Antiviral chemotherapy for the treatment of hepatitis B virus infections. Gastroenterology 2000; 118: S83–103.

Leung N. Clinical experience with lamivudine. Seminars in Liver Disease 2002; 22(Suppl. 1): 15–21.

Liaw Y.F. , Leung N.W. , Chang T.T. , Guan R. , Tai D.I. , Ng K.Y. , Chien R.N. , Dent J. , Roman L. , Edmundson S. , & Lai C.L. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. Gastroenterology 2000; 119: 172–180.

Hadziyannis S.J. , Papatheodoridis G. V. , Dimou E. , Laras A. , & Papaioannou C. Efficacy of long-term lamivudine monotherapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Hepatology 2000; 32: 847–851.

Delaney W.E. IV , Locarnini S. , & Shaw T. Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation. Antiviral Chemistry & Chemotherapy 2001; 12: 1–35.

Delaney W.E. IV , Bartholomeusz A. , & Locarnini S. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opinion on Investigational Drugs 2002; 11(2): 169–187.

Leung N.W. , Lai C.L. , Chang T.T. , Guan R. , Lee C.M. , Ng K.Y. , Lim S.G. , Wu P.C. , Dent J.C. , Edmundson S. , Condreay L.D. , & Chien R.N. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy. Hepatology 2001; 33: 1527–1532.

Papatheodoridis G. V. , Dimou E. , Laras A. , Papadimitropoulos V. , & Hadziyannis S.J. Course of virologic breakthroughs under long-term lamivudine in HBeAg-negative precore mutant HBV liver disease. Hepatology 2002; 36: 219–226.

Melegari M. , Scaglioni P. , & Wands J. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 1998; 27: 628–633.

Bartholomeusz A. , & Locarnini S. Hepatitis B virus mutants and fulminant hepatitis B: fitness plus phenotype. Hepatology 2001; 34: 432–435.

Liaw Y.F. , Chien R.N. , Yeh C.T. , Tsai S.L. , & Chu C.M. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 567–572.

Heathcote J. Treatment of HBe antigen-positive chronic hepatitis B. Seminars in Liver Disease 2003; 23: 69–79.

Liaw Y.F. , Chien R.N. , & Yeh C.T. No benefit to continue lamivudine therapy after emergence of YMDD mutations. Antiviral Therapy 2004; 9: 257–262.

Perrillo R. , Hann H.W. , Mutimer D. , Willems B. , Leung N. , Lee W.M. , Moorat A. , Gardner S. , Woessner M. , Bourne E. , Brosgart C.L. , & Schiff E. Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. Gastroenterology 2004; 126: 81–90.

Peters M.G. , Hann Hw H. , Martin P. , Heathcote E.J. , Buggisch P. , Rubin R. , Bourliere M. , Kowdley K. , Trepo C. , Gray Df D. , Sullivan M. , Kleber K. , Ebrahimi R. , Xiong S. , & Brosgart C.L. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91–101.

Ono S.K. , Kato N. , Shiratori Y. , Kato J. , Goto T. , Schinazi R. F. , Carrilho F.J. , & Omata M. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. Journal of Clinical Investigation 2001; 107: 449–455.

Ayres A. , Bartholomeusz A. , Lau G.K. , Lam K.C. , Lee J.Y. , & Locarnini S. Lamivudine and famciclovir resistant hepatitis B virus associated with fatal hepatic failure. Journal of Clinical Virology 2003; 27: 111–116.

Bock C. , Tillmann H. , Torresi J. , Klempnauer J. , Locarnini S. , Manns M. , & Trautwein C. HBV polymerase mutants with enhanced replication selected during lamivudine therapy result in sudden onset of liver failure. Gastroenterology 2002; 122: 264–273.

De Man R.A. , Bartholomeusz A. , Niesters H.G.M. , Zondervan P.E. , & Locarnini S. The sequential occurrence of viral mutations in a liver transplant recipient re-infected with hepatitis B virus: hepatitis B immune globulin escape, famciclovir non-response, followed by lamivudine resistance resulting in graft loss. Journal of Hepatology 1998; 29: 669–675.

Ogata N. , Fujii K. , Takigawa S. , Nomoto M. , Ichida T. , & Asakura H. Novel patterns of amino acid mutations in the hepatitis B virus polymerase in association with resistance to lamivudine therapy in Japanese patients with chronic hepatitis B. Journal of Medical Virology 1999; 59: 270–276.

Ohkubo K. , Kato Y. , Ichikawa T. , Kajiya Y. , Takeda Y. , Higashi S. , Hamasaki K. , Nakao K. , Nakata K. , & Eguchi K. Viral load is a significant prognostic factor for hepatitis B virus-associated hepatocellular carcinoma. Cancer 2002; 94: 2663–2668.

Feld J. , Lee J.Y. , & Locarnini S. New targets and possible new therapeutic approaches in the chemotherapy of chronic hepatitis B. Hepatology 2003; 38: 545–553.

Richman D.D. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32: 866–867.

Marcellin P. , Chang T.T. , Lim S.G. , Tong M.J. , Sievert W. , Shiffman M.L. , Jeffers L. , Goodman Z. , Wulfsohn M.S. , Xiong S. , Fry J. , & Brosgart C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. New England Journal of Medicine 2003; 348: 808–816.

Hadziyannis S.J. , Tassopoulos N.C. , Heathcote E.J. , Chang T.T. , Kitis G. , Rizzetto M. , Marcellin P. , Lim G. , Goodman Z. , Wulfsohn M.S. , Xiong S. , Fry J. , & Brosgart C.L. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. New England Journal of Medicine 2003; 348: 800–807.

Chin R. , Shaw T. , Torresi J. , Sozzi V. , Trautwein C. , Bock T. , Manns M. , Isom H. , Furman P. , & Locarnini S. In vitro susceptibilities of wild-type or drug-resistant hepatitis B virus to (–)-beta-D-2,6-diaminopurine dioxolane and 2′-fluoro-5-methyl-beta-L-arabinofuranosyluracil. Antimicrobial Agents & Chemotherapy 2001; 45: 2495–2501.

Shaw T. , Bowden S. , & Locarnini S. Rescue therapy for drug resistant hepatitis B: another argument for combination chemotherapy? Gastroenterology 2004; 126: 343–347.

Westland C.E. , Yang H. , Delaney W.E. , Gibbs C.S. , Miller M.D. , Wulfsohn M. , Fry J. , Brosgart C.L. , & Xiong S. Week 48 resistance surveillance in two Phase 3 clinical studies of adefovir dipivoxil for chronic hepatitis B. Hepatology 2003; 38: 96–103.

Angus P. , Vaughan R. , Xiong S. , Yang H. , Delaney W.E. , Gibbs C. , Brosgart C. , Colledge D. , Edwards R. , Ayres A. , Bartholomeusz A. , & Locarnini S. Resistance to adefovir dipivoxil therapy associated with development of a novel mutation in the HBV polymerase. Gastroenterology 2003; 125: 292–297.

Levine S. , Hernandez D. , Yamanaka G. , Zhang S. , Rose R. , Weinheimer S. , & Colonno R.J. Efficacies of entecavir against lamivudine-resistant hepatitis B virus replication and recombinant polymerases in vitro. Antimicrobial Agents & Chemotherapy 2002; 46: 2525–2532.

Lai C.L. , Rosmawati M. , Lao J. , Van Vlierberghe H. , Anderson F.H. , Thomas N. , & Dehertogh D. Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. Gastroenterology 2002; 123: 1831–1838.

Westland C. , Villeneuve J. P. , Terrault N. , Zoulim F. , Brosgart C. , Wulfsohn M. , Miller M. , & Xiong S. Resistance surveillance of liver transplantation patients with lamivudine-resistant hepatitis B virus (HBV) after 96 weeks of adefovir dipixovil treatment. Hepatology 2003; 38: 160A.

Colledge D. , Civitico G. , Locarnini S. , & Shaw T. In vitro antihepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrobial Agents & Chemotherapy 2000; 44: 551–560.

Wang J.H. , Lu S.N. , Lee C.M. , Lee J.F. , & Chou Y.P. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scandinavian Journal of Gastroenterology 2002; 37: 366–369.

Kim J.W. , Lee H.S. , Woo G.H. , Yoon J.H. , Jang J.J. , Chi J.G. , & Kim C.Y. Fatal submassive hepatic necrosis associated with tyrosine-methionine-aspartate-aspartate-motif mutation of hepatitis B virus after long-term lamivudine therapy. Clinical Infectious Disease 2001; 33: 403–405.

Perrillo R. , Schiff E. , Yoshida E. , Statler A. , Hirsch K. , Wright T. , Gutfreund K. , Lamy P. , & Murray A. Adefovir dipivoxil for the treatment of lamivudine-resistant hepatitis B mutants. Hepatology 2000; 32: 129–134.

Locarnini S. , & Birch C. Antiviral chemotherapy for chronic hepatitis B infection: lessons learned from treating HIV infected patients. Journal of Hepatology 1999; 30: 536–550.

Shaw T. , Bowden S. , & Locarnini S. Chemotherapy for hepatitis B: new treatment options necessitate reappraisal of traditional endpoints. Gastroenterology 2002; 123: 2135–2140.

Liaw Y. , Sung J. , Chow W. , Shue K. , Keene O. , & Farrell G. Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial. Hepatology 2003; 38: 262A.

Mutimer D. , Pillay D. , Shields P. , Cane P. , Ratcliffe D. , Martin B. , Buchan S. , Boxall L. , O'Donnell K. , Shaw J. , Hubscher S. , & Elias E. Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 2000; 46: 107–113.